Introduction
Despite its conceptual simplicity, and remarkable successes in small and large animal models of disease, gene therapy has proven difficult to extend successfully to humans. The most clear-cut examples of therapeutic success to date have come in a handful of immunodeficiency disorders, in which gene transfer was carried out by ex vivo transduction of hematopoietic cells using retroviral vectors. Even these, however, have not been entirely free of complications. [1] [2] [3] Perhaps the most important achievement of the past 15 years of clinical investigation in gene transfer has been the development of a reasonably complete list of problems that must now be solved in order to make successful treatment a reality in humans (Table 1) .
In assessing the pace of progress in clinical gene transfer, there are two factors that must be taken into account. The first is that, for the development of entirely new classes of therapeutics, the period required from first clinical testing to robust clinical applications can easily range from 20 to 30 years. Clinical development of bone marrow transplantation and therapeutic monoclonal antibodies both illustrate this point. Second, gene transfer vectors, consisting of both protein and nucleicacid components, are perhaps the most complex biologic product yet investigated. In this context, current levels of progress seem reasonable.
For AAV-mediated gene transfer, initial problems centered on achieving efficacy in animal models and achieving adequate and reproducible small-scale manufacturing of product. These two problems were clearly linked, but were also largely solved earlier in this decade (large-scale manufacturing remains a challenge). For applications in target tissues of interest for a disease like hemophilia, it has now become clear that the primary problem to be solved for successful human application will be controlling immune responses to vector and/or to transgene. It is perhaps no accident that these problems were first highlighted in the hemophilia trials. Hemophilia has the advantage that the therapeutic endpoints are quantitative (circulating clotting factor levels) and easily measured (by tests available in any hospital coagulation laboratory). Thus changes in level of expression are easily tracked and can be correlated temporally with measures of immune responses and resulting damage to target tissue. These trials have basically served to underscore that translation of in vivo gene therapy to humans represents a new problem in biology, as we attempt to delineate and then control the human immune response to a new molecular entity that structurally resembles a virus, but that fails to behave like one, as it lacks the capacity to direct the synthesis of viral proteins, and is not capable of in vivo replication.
Hemophilia B is an X-linked bleeding disorder caused by mutations in the gene encoding coagulation factor IX (F.IX). Hemophilia B affects approximately 1 in 30 000 men. Patients are grouped according to circulating levels of F.IX, which correlate closely with clinical severity.
Thus mild, moderate and severe hemophilia refer to plasma concentrations of F.IX of 5-25%, 1-5% and o1% of normal respectively. The disease is currently treated by intravenous infusion of protein concentrates, either plasma-derived or recombinant, but the short half-life of F.IX in the circulation and the expense and inconvenience of these treatments have motivated efforts to develop other therapies.
The largest category of patients with hemophilia B have severe disease, with o1% normal circulating levels of F.IX activity. Improvement of levels to above 1% results in improvement of symptoms, and is sufficient to prevent most spontaneous and nearly all life-threatening bleeding episodes. 4 Studies have shown that maintaining patients with severe hemophilia on prophylaxis regimens can minimize the risk of serious bleeding episodes and of cumulative damage to the joints. 5, 6 The goal of prophylaxis therapy is to maintain trough factor levels 41% of normal. On the basis of the history of the disease in patients with baseline levels above 1%, and prophylaxis studies in the severe phenotype that minimize bleeding complications, the minimum goal of gene therapy for hemophilia B is sustained expression of F.IX levels above 1%.
Several features make hemophilia B an attractive model for gene therapy. Precise regulation of transgene expression is not required, and the therapeutic range of circulating levels of clotting factor is wide, ranging from 41 to 100% of normal. Circulating levels of clotting factor correlate well with the clinical symptomatology of the disease, and determination of levels can be carried out through simple clotting assays. Although clotting factors are normally synthesized in hepatocytes, it has been shown that biologically active clotting factors can be synthesized in a wide variety of tissues, including muscle cells, endothelial cells and fibroblasts; [7] [8] [9] in fact, the currently marketed recombinant factors are manufactured in Chinese hamster ovary cells.
The relatively small size of the F9 coding sequence (1.4 kb) makes it the preferred starting point for gene transfer studies of hemophilia, as both the coding sequence and additional regulatory elements are easily accommodated by most vectors. Hemophilia A, caused by mutations in the F8 gene, has a coding sequence of 47 kb, and even the sequence for a trimmed down B-domain-deleted construct is 4.4 kb, leaving little room in an AAV vector for additional regulatory elements. The initial gene therapy approaches for hemophilia B have used AAV vectors, delivering the cDNA to both skeletal muscle (in the first trial) and liver (in the second). AAV vector tropism for post-mitotic cells of interest, and stabilization of the genome in a predominantly nonintegrated form make it an attractive vehicle for gene transfer for genetic disease. [7] [8] [9] [10] Its low immunogenicity and lack of toxicity are also advantages from a therapeutic standpoint. There are no identifiable diseases or symptoms associated with wild-type AAV infection.
This review presents some of the work in the field of gene therapy for hemophilia B, including lessons learned from large animal models of the disease and in human clinical trials. Some of the barriers to successful gene transfer in humans are explored in the context of previously published data.
AAV-mediated muscle-directed gene transfer
Early work used recombinant AAV vectors for expression of F.IX under the direction of a cytomegalovirus (CMV) IE promoter. In 1999, Herzog et al. Three of the five dogs had no evidence of antibodies to the transgene product. The two dogs that showed evidence of antibody formation received the two highest doses of vector in the study. One dog had a transient noninhibitory antibody to canine F.IX detectable on day 14 after injection, with antibody levels gradually decreasing until they were undetectable by week 8. One dog had transient neutralizing antibodies to cF.IX present from day 14 to day 35, returning to undetectable levels by week 15. This correlated with transient declines in plasma F.IX levels. This study demonstrated that intramuscular injection of AAV-cFIX in a large animal model of the disease is safe, and that F.IX levels achievable are dose dependant, as is the risk of inhibitor formation when direct intramuscular injection is used.
On the basis of promising preclinical data in a large animal model of the disease, the first phase I/II clinical trial was carried out in humans in an open label, doseescalation study. A total of eight adult subjects with severe hemophilia B were given intramuscular injections of an AAV vector expressing human F.IX. 10, 13 Three dose cohorts, ranging up to a dose of 1.8 Â 10 12 vg per kg, were included, and the study was limited to subjects with missense mutations in the F9 gene, to minimize the risk Problems and prospects of AAV-mediated gene transfer NC Hasbrouck and KA High of inhibitory antibodies to F.IX. Vector administration was well tolerated in all subjects. Muscle biopsies performed 2 months, 6 months, and 12 months after vector injection showed no evidence of inflammation or muscle injury, and immunohistochemical staining was positive for F.IX both intracellularly and in the extracellular space. There was no evidence of inhibitor formation, monitored by a Bethesda assay and by Western blotting for noninhibitory anti-FIX antibodies for 6 months. No evidence of germline transmission of vector sequences was detected using a sensitive PCR assay for vector sequences on DNA extracted from semen. Four of the eight subjects had intermittent measureable factor levels above baseline, however, the doses used in this study did not result in sustained factor levels 41% (as was predicted by the large animal model, where a dose of 8.5 Â 10 12 vg/kg was necessary for a sustained therapeutic effect). Further dose escalation, however, appeared impractical using this method. Studies in large animal models had shown that the risk of inhibitor formation increases with increasing dose per site, 14 and dosing to achieve therapeutic levels of F.IX would require increasing numbers of injection sites substantially above the 80-95 injections required to safely deliver a dose of 1.8 Â 10 12 vg/kg. As the clinical trial of AAV-hF.IX into skeletal muscle proved to be safe, and showed evidence of F.IX on immunofluorescent staining of muscle biopsies, studies began to focus on methods for transducing large numbers of muscle fibers without hundreds of i.m. injections. Arruda et al. 15 showed that a technique of isolated limb perfusion achieved extensive transduction with AAV to the muscle (previously used for the delivery of high-dose chemotherapy to a single limb). The femoral artery and vein are exposed in a surgical procedure and a tourniquet is tied at the level of the hip joint. A vasodilatory agent is used, and the limb circulation is infused with vector mixed with histamine to induce vascular leakage. The limb circulation is then flushed and the tourniquets removed. Three hemophilia B dogs with disease due to missense mutations were injected with 3.7 Â 10 12 , 1.7 Â 10 12 or 3.0 Â 10 12 vg per kg of AAV canine F.IX under the direction of a CMV promoter. The animals were immunosuppressed for a period of 6 weeks with cyclophosphamide to reduce the risk of formation of inhibitory antibodies to F.IX, as seen in prior animal studies. 14, 16, 17 All three animals achieved long-term expression of canine F.IX at therapeutic levels, without evidence of antibody formation, at 15, 5.2 and 4.2% respectively, for over 3 years. This route of administration proved to be more effective than that of IM injections, however, the need for an invasive surgical procedure and the inability to use histamine as a vascular permeabilizing agent in humans led to the investigation of other methods of delivery. More recently, development of a simple procedure that relies on increased hydrostatic pressure rather than a pharmacologically induced vascular leak to achieve high-level transduction of muscle via the vascular system 18 has resulted in high-level F.IX expression in hemophilic dogs, but short-term immunosuppression with cyclophosphamide was still required to prevent formation of inhibitory antibodies to F.IX. 15 This procedure has not yet been evaluated in human subjects.
Collectively, the data in animal models suggest that the major risk in AAV-mediated F9 gene transfer to skeletal muscle is a risk of antibody formation to F.IX. Factors that appear to affect this risk include degree of tolerance to F.IX in the recipient (underlying nonsense mutations are consistently associated with antibody formation, missense mutations only with high doses), the dose of vector (high doses are more likely to lead to inhibitor formation) and vector serotype (more efficient transduction of skeletal muscle enhances the likelihood of inhibitor formation). The latter two factors underscore the role of antigen concentration in promoting antibody formation.
AAV-mediated, liver-directed gene transfer
In 1997, Snyder et al. 19 published data on the first successful transduction of the liver in mice using recombinant AAV vectors. C57B1/6 mice were infused with 2. ; these levels were dosedependent and sustained for 9 months (the duration of the study). No hepatic injury was seen, as evidenced by normal serum glutamic pyruvic transaminase levels and the lack of histological infiltrates in the liver at 1 week and 7 weeks after AAV administration. Portal vein infusion proved to be a safe delivery system for AAVhF.IX infusion in mice, and therapeutic levels of human F.IX were achieved and sustained. This led to further studies in large animal models of hemophilia B to investigate the feasibility of this method in future human clinical trials.
A study published by Mount et al. 20 in 2002 showed that sustained correction of F.IX by liver-directed gene transfer is achievable even in a large animal model of severe hemophilia B prone to inhibitor formation. Four dogs with either a F.IX null mutation or a F.IX missense mutation were injected with doses ranging from 8 Â 10 11 to 3.4 Â 10 12 vg per kg of AAV-(ApoE) 4 /hAAT-cFIX vector under the direction of a liver specific promoter. Three of the four animals had phenotypic correction of F.IX, including two of the three animals prone to inhibitor formation due to the F.IX null mutation. Levels of canine F.IX achieved and sustained were well within the therapeutic range, ranging from 220 to 590 ng ml À1 for over 6 months, the duration of the study. Loss of F.IX expression in the fourth animal was due to formation of inhibitory antibodies to canine F.IX first noted at week 5. Of note, this animal had a history of (an unrelated) pyruvate kinase deficiency, which can be associated with antibodies against red blood cells, antiphospholipid antibodies, and liver pathology secondary to iron overload in dogs. The encouraging findings of sustained expression of F.IX in this large animal model led to a clinical trial of AAV-mediated liver-directed gene transfer in patients with severe hemophilia B, although the occurrence of a F.IX inhibitor in one animal raised a cautionary note.
Immune responses to the transgene product are an unwanted outcome of gene replacement strategies, Problems and prospects of AAV-mediated gene transfer NC Hasbrouck and KA High making this study important for the field, as it suggested that AAV-mediated liver-directed gene transfer was no more likely than protein concentrate infusion to result in inhibitor formation. Subsequent studies by Mingozzi and colleagues showed that hepatic gene transfer using an AAV vector promotes induction of tolerance to the transgene product, making liver an attractive target tissue for AAV-mediated gene transfer. 21 In the clinical study, a recombinant AAV2 vector expressing human F.IX was infused through the hepatic artery in subjects with severe hemophilia B in an open label, dose-escalation study. 12 Subjects in three dose cohorts were injected with 8 Â 10 10 , 4 Â 10 11 or 2 Â 10 12 vg per kg. Subjects receiving doses of 8 Â 10 10 or 4 Â 10 11 vg per kg had no evidence of liver toxicity, but no circulating levels of F.IX above 1%. The first subject receiving a dose of 2 Â 10 12 vg per kg achieved maximum F.IX levels above 11% 2 weeks after vector infusion, but in contrast to results in animal models exhibited a gradual decline in factor levels to o1% by 10 weeks after vector infusion. This was accompanied by an asymptomatic transaminase elevation beginning 4 weeks after vector infusion, with a gradual decline to baseline normal levels coinciding with the loss of F.IX expression (Figure 1) . In a subsequent subject, who received a lower dose of 4 Â 10 11 vg per kg, lymphocytes were drawn before and after vector infusion, to assess immune responses to both AAV capsid and F.IX, the only two elements in the vector. This dose was again documented to be subtherapeutic, but a small rise in liver enzymes was again observed, with kinetics similar to that seen in the patient infused at the higher dose. Peripheral blood mononuclear cells (PBMCs) from the subject were stimulated with pools of peptides derived from either the AAV capsid sequence or the F.IX sequence, and assessed for interferon-g secretion by the Enzyme-linked immunosorbent spot assay (ELISPOT). This documented a response to capsid but not to F.IX. 12 The peptides were arrayed in a matrix such that positive responses in any two orthogonal pools defined a unique peptide epitope; these data combined with high-resolution human lymphocyte antigen (HLA) typing and prediction algorithms for identifying peptide sequences with highest binding affinity to the subject's HLA molecules defined both a CD4 + and a CD8 + T-cell epitope within the capsid sequence. Subsequent generation of a pentamer composed of an HLA-B*0702 molecule loaded with the immunodominant epitope from the capsid (VPQY-GYLTL) allowed direct determination of frequencies of capsid-specific CD8 + T cells in the peripheral blood of the subject. 22 This showed that the capsid-specific CD8 + Tcell population expanded and contracted in a time course that matched the rise and fall of liver enzymes. These CD8 + T cells were able to lyse HLA-matched cells loaded with the immunodominant peptide, and moreover they proliferate upon exposure to other AAV serotypes, suggesting that the immune response will not easily be circumvented by switching vector serotype.
These data certainly suggest that the transaminase elevation, accompanied by a decline in F.IX levels, arose from specific destruction of the transduced cells. The question then arises as to what antigen or antigens were targeted by the immune response. The data from these studies favor AAV capsid as the offending antigen. However, as the vector genome does not encode capsid, the question arises as to how capsid-derived sequences are being loaded onto MHC Class I molecules. Although Class I molecules favor presentation of peptides derived from de novo produced proteins, alternative pathways exist that allow presentation of peptides derived from proteins taken up passively by the cell. These relatively inefficient pathways may have sufficed for recognition and destruction of AAV-transduced cells by capsidspecific CD8 + effector cells. Against this hypothesis is that it has been impossible to demonstrate a similar phenomenon in animal models of AAV transduction, even in mice immunized to develop a population of capsid-specific CD8 + T cells in the periphery. [23] [24] [25] It is perhaps important to keep in mind that human exposure to AAV, resulting from infection with a wild-type virus, typically with co-infecting adenovirus, may constitute a substantially different type of immune priming event compared to the experimental mouse studies, where empty capsids or noninfectious vector were used to prime the response.
Alternative hypotheses that have been proposed to explain these findings include packaging of the rep/cap plasmid used in vector production, and translation of alternate open reading frames in the F.IX cassette that are then recognized as foreign by the host immune response. The first has been extensively explored and appears to be less likely. 26 The second hypothesis suffers from the same weakness as the one proposed by Mingozzi et al., 22 namely it is difficult to understand why it was never observed in animal models. In particular there are a number of published studies in which nonhuman primates have been infused with AAV vectors encoding human F.IX, and no loss of expression accompanied by transaminase elevation has been demonstrated. [27] [28] [29] [30] Another proposal advanced by Wilson and colleagues suggests that use of alternate serotypes or capsid isolates may avoid the immune response encountered with AAV-2 vectors. This is based on an observation reported by this group that AAV variants that possess a heparin-binding motif are taken up efficiently by dendritic cells and activate CD8 + T cells more readily. 31 This would imply that switching to a serotype that lacks the heparinbinding motif may resolve issues related to the immune response. This hypothesis will be tested in a proposed human trial of an AAV-8 vector expressing F.IX. A challenge in this trial will be to choose a safe but effective starting dose, as AAV- 8 has not yet been administered to human subjects. The AAV-2-F.IX trial will also move forward, but a short course of immunosuppression will be added at the time of vector administration, to blunt the immune response to the transduced cells until the 
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Problems and prospects of AAV-mediated gene transfer NC Hasbrouck and KA High capsid is degraded and cleared from the cells. This strategy of short-term immunosuppression with AAV vector administration has already been carried out in a trial for lipoprotein lipase deficiency, in which an AAV vector is administered intramuscularly. 32 The starting vector dose in the amended AAV-F.IX trial will be close to that that gave circulating F.IX levels of 10-12% in the previous iteration of the trial.
A final problem that is as yet theoretical in human AAV studies is the risk of insertional mutagenesis. Studies in mice suggest that AAV vectors are predominantly nonintegrating, 33 and a wealth of experience in the field had failed to uncover any evidence of tumor formation as a result of AAV transduction, save in a single mouse disease model of mucopolysaccharidosis type VII. 34 A recent brief report expanded on these data by reporting that, in the tumor tissue, the vector appeared to have integrated in a region rich in micro-RNA sequences on mouse chromosome 12. 35 On the other hand, follow-up periods ranging up to 9 years in hemophilic dogs have failed to reveal any evidence of tumor formation in these animals (TC Nichols, KA High, VA Arroda, unpublished data). Future studies will be aimed at determining sites of and mechanisms for AAV integration in target tissues of interest. If problems related to the human immune response are not solved, then consequences of long-term integration are unlikely to materialize, as the transduced cells will not persist in the recipient.
Summary
What conclusions can be drawn from this work so far? First it is clear that AAV-2 can transduce human hepatocytes and direct levels of expression adequate to treat hemophilia. Second it appears that an immune response to some element either in or encoded by the vector resulted in clearance of the transduced cells. Among the potential offending antigens, a CD8 + T-cell response to an epitope in the wild-type protein would present the most difficult obstacle; fortunately, there is no evidence for this in AAV-mediated hepatic gene transfer. If as our studies suggest the offending antigen is incoming capsid, then transient immunosuppression until capsid sequences have been degraded and cleared from the transduced cell may allow long-term expression, and the problem becomes to determine how long this will take. In this circumstance, it also becomes important to maximize the ratio of full:empty capsid, as empty capsid would be likely to promote immunity to the transduced cell without resulting in improved transduction. Perhaps the most valuable lesson to be gained from these studies is the importance of thoroughly analyzing even modest safety signals, as careful delineation of the causes of these may determine the difference between success and failure in clinical gene therapy. Finally, clinical trials of viral vector-mediated gene therapy have allowed us to probe complexities of human physiology and immunology that have often not been predicted by animal studies. Rigorous analysis of the problems encountered in clinical gene transfer extends our knowledge of human biology and highlights differences in responses among species that may have implications for development of a broad range of novel therapeutics.
